RxDoctor Payments Data

Andrew McDavid, MD

Interventional Pain Medicine · Killeen, TXNPI 1477514479

Payments from drug & device makers

$10,918in general payments, 2019–2025

Across 636 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • AbbVie$851
  • Boston Scientific$427
  • Vertos Medical, Inc.$237
  • Curonix LLC$197
  • Nalu Medical, Inc.$137
  • plus $734 from 17 others

What the payments were for

  • Food & beverage$10,918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,918 in reported general payments places this provider in the 55th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$296,275
Medicare patients
338
Services billed
5,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,268$76,158
Pregabalin669$13,407
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen393$13,362
Buprenorphine47$12,170
BelbucaBuprenorphine Hcl13$11,159
Lidocaine74$10,913
Gabapentin427$7,008
LinzessLinaclotide13$6,862
Tizanidine Hcl294$3,884
Methocarbamol154$3,284
Tramadol Hcl299$3,086
Naloxone Hcl48$3,055
Diclofenac Sodium30$2,860
Acetaminophen-CodeineAcetaminophen With Codeine107$2,183
Etodolac49$2,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$851$6,86213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Killeen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →